Axsome Therapeutics (NASDAQ:AXSM) posted its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01, MarketWatch Earnings reports.
Shares of NASDAQ AXSM traded up $0.23 during mid-day trading on Friday, reaching $10.94. The company had a trading volume of 12,069 shares, compared to its average volume of 2,634,489. The company has a debt-to-equity ratio of 6.00, a quick ratio of 1.46 and a current ratio of 1.46. Axsome Therapeutics has a one year low of $1.94 and a one year high of $10.89. The stock has a market capitalization of $302.90 million, a P/E ratio of -8.72 and a beta of 3.32.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Alethea Capital Management LLC increased its position in shares of Axsome Therapeutics by 65.9% in the fourth quarter. Alethea Capital Management LLC now owns 908,429 shares of the company’s stock worth $2,562,000 after purchasing an additional 360,986 shares during the period. Sio Capital Management LLC boosted its stake in Axsome Therapeutics by 115.5% in the third quarter. Sio Capital Management LLC now owns 416,458 shares of the company’s stock valued at $1,437,000 after buying an additional 223,168 shares in the last quarter. Millennium Management LLC acquired a new stake in Axsome Therapeutics in the fourth quarter valued at about $871,000. BlackRock Inc. boosted its stake in Axsome Therapeutics by 14.6% in the fourth quarter. BlackRock Inc. now owns 64,049 shares of the company’s stock valued at $181,000 after buying an additional 8,137 shares in the last quarter. Finally, Worth Venture Partners LLC acquired a new stake in Axsome Therapeutics in the third quarter valued at about $138,000. Institutional investors own 12.84% of the company’s stock.
AXSM has been the topic of several recent research reports. BTIG Research increased their price objective on Axsome Therapeutics to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, January 8th. Cantor Fitzgerald set a $16.00 price objective on Axsome Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 10th. HC Wainwright raised their price target on Axsome Therapeutics to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 7th. Zacks Investment Research upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 5th. Finally, ValuEngine upgraded Axsome Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $24.75.
WARNING: “Axsome Therapeutics (AXSM) Issues Quarterly Earnings Results” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2019/03/15/axsome-therapeutics-axsm-issues-quarterly-earnings-results.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Recommended Story: How is a Moving Average Calculated?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.